** Medical device maker Edward Lifesciences' shares EW.N rise 4.4% to $74 premarket

** Co on Tuesday reported Q4 profit of 59 cents/share, beating analyst est of 55 cents/share - LSEG data

** Co posted Q4 total sales of $1.39 billion, higher than analyst est of $1.35 bln

** EW's lead product, transcatheter aortic valve replacement (TAVR) device, brought in Q4 sales of $1.04 billion vs analyst est of $1.01 billion

** At least three brokerages raised PT on the stock following results

** Brokerage William Blair says EW is well positioned to meet its financial goals this year

** Co's performance could be boosted by potential insurance coverage for its tricuspid valve replacement devices, broader approval of TAVR procedures and regulatory approval of the Sapien M3 heart valve in the U.S and the EU, the brokerage said

** Stock fell 16.5% in the last 12 months

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com;))